3D printing MicroFactory for amorphous solid dispersion formulations

Elke Prasad; Jill Hueckman; Ecaterina Bordos; John Robertson; Gavin W. Halbert

3D printing MicroFactory for amorphous solid dispersion formulations

Elke Prasad, Jill Hueckman, Ecaterina Bordos, John Robertson, Gavin W. Halbert

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to conference › Poster

32 Downloads (Pure)

Abstract

This study utilised the HUB Additive-ManufacturingMicroFactory as an enabler for streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® as a superior polymer to form stable ASD formulation with Ritonavir. The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

Original language	English
Number of pages	1
Publication status	Published - 14 Jul 2024
Event	CMAC Summer School 2024 - Dunblane, United Kingdom Duration: 10 Jul 2023 → 14 Jul 2024

Conference

Conference	CMAC Summer School 2024
Country/Territory	United Kingdom
City	Dunblane
Period	10/07/23 → 14/07/24

Funding

The authors would like to acknowledge that this work was carried out in the CMAC National Facility supported by the EPSRC (Grant ref EP/P006965/1) and by UKRPIF (UK Research Partnership Fund) award from the Higher Education Funding Council for England (HEFCE) (Grant ref HH13054). G. W. Halbert is funded by Cancer Research UK (C149/A20496). We would like to thank the National Facility team, in particular Martin Ward, Rachel Feeney and Thomas McGlone, for their support in this project. We would also like to thank BASF for the donation of the Soluplus® polymer.

Keywords

3D printing
MicroFactory
amorphous solid dispersion
Ritonavir

Access to Document

Prasad-etal-CMAC-2024-3D-printing-MicroFactory-for-amorphous-solid-dispersion-formulationsFinal published version, 1.2 MBLicence: Strath_1

Cite this

@conference{8610529808c5424aa705d7bc1b19dea6,

title = "3D printing MicroFactory for amorphous solid dispersion formulations",

abstract = "This study utilised the HUB Additive-ManufacturingMicroFactory as an enabler for streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus{\textregistered} (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus{\textregistered} as a superior polymer to form stable ASD formulation with Ritonavir. The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus{\textregistered} were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).",

keywords = "3D printing, MicroFactory, amorphous solid dispersion, Ritonavir",

author = "Elke Prasad and Jill Hueckman and Ecaterina Bordos and John Robertson and Halbert, {Gavin W.}",

year = "2024",

month = jul,

day = "14",

language = "English",

note = "CMAC Summer School 2024 ; Conference date: 10-07-2023 Through 14-07-2024",

}

TY - CONF

T1 - 3D printing MicroFactory for amorphous solid dispersion formulations

AU - Prasad, Elke

AU - Hueckman, Jill

AU - Bordos, Ecaterina

AU - Robertson, John

AU - Halbert, Gavin W.

PY - 2024/7/14

Y1 - 2024/7/14

N2 - This study utilised the HUB Additive-ManufacturingMicroFactory as an enabler for streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® as a superior polymer to form stable ASD formulation with Ritonavir. The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

AB - This study utilised the HUB Additive-ManufacturingMicroFactory as an enabler for streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® as a superior polymer to form stable ASD formulation with Ritonavir. The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

KW - 3D printing

KW - MicroFactory

KW - amorphous solid dispersion

KW - Ritonavir

UR - https://cmac.ac.uk/news-database/cmac-summer-school-2024

M3 - Poster

T2 - CMAC Summer School 2024

Y2 - 10 July 2023 through 14 July 2024

ER -

3D printing MicroFactory for amorphous solid dispersion formulations

Abstract

Conference

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Additive manufacturing MicroFactory for amorphous solid dispersion formulations

Cite this